Skip to main content

Table 1 Baseline characteristics by treatment

From: Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

Adjuvant chemotherapy Epirubicin No epirubicin None P*
Total patients No. (%) 205 (27.5%) 113 (15.2%) 427 (57.3%)  
Age in years (mean, SD) 53.0 (10.5) 55.6 (12.6) 60.5 (12.0) < 0.001
Tumor size     < 0.001
   ≤ T1 (≤ 20 mm) 75 (36.6%) 59 (52.2%) 296 (69.3%)  
   ≥ T2 127 (62.0%) 50 (44.2%) 121 (28.3%)  
   unknown 3 (1.5%) 4 (3.5%) 10 (2.3%)  
Lymph nodes     < 0.001
   0 32 (15.6%) 45 (39.8%) 262 (61.4%)  
   ≥ 1 162 (79.0%) 57 (50.4%) 131 (30.7%)  
   unknown 11 (5.4%) 11 (9.7%) 34 (8.0%)  
Grade     < 0.001
   1 3 (1.5%) 4 (3.5%) 45 (10.5%)  
   2 63 (30.7%) 31 (27.4%) 260 (60.9%)  
   > 2 128 (62.4%) 77 (68.1%) 107 (25.1%)  
   Unknown 11 (5.4%) 1 (0.9%) 15 (3.5%)  
  1. * P-values are indicated for the comparison of patients treated with adjuvant chemotherapy (with or without epirubicin) vs. patients not treated with any adjuvant chemotherapy.
  2. SD, standard deviation